Comparative Pharmacology
Head-to-head clinical analysis: BENDECTIN versus EMEND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENDECTIN versus EMEND.
BENDECTIN vs EMEND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of doxylamine (antihistamine) and pyridoxine (vitamin B6). Doxylamine blocks histamine H1 receptors, reducing nausea and vomiting. Pyridoxine acts as a cofactor in neurotransmitter synthesis, modulating nausea pathways.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
10 mg doxylamine succinate + 10 mg pyridoxine hydrochloride orally once daily at bedtime, increased to twice daily (one tablet in morning and one at bedtime) and then three times daily (one tablet in morning, one in midafternoon, and one at bedtime) as needed, max 4 tablets per day.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
None Documented
None Documented
Doxylamine: 10-12 hours (range 6-15h) in healthy adults; prolonged in hepatic impairment or elderly. Pyridoxine: 15-20 days (as pyridoxal phosphate in tissues); elimination half-life of pyridoxine per se is 2-3 hours.
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
Renal: mostly as metabolites. Doxylamine: ~60% as unchanged drug and metabolites; pyridoxine: ~70-80% as metabolites (primarily 4-pyridoxic acid). Fecal: minimal (<10%) for both components.
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Category C
Category C
Antiemetic
Antiemetic